Page 76 - 51 the significance--29.2_opt
P. 76

42.  Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs.
             pioglitazone when added to metformin: a 24-week, randomized, double-blind
             study. Diabetes, obesity & metabolism 2008;10(1):82-90.
          43.  Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of
             the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2
             diabetes. Diabetes care 2004;27(12):2874-80.
          44.  Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahren B, Byiers S, et al. Fifty-two-
             week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 dia-
             betes mellitus inadequately controlled on metformin monotherapy. Diabetes,
             obesity & metabolism 2009;11(2):157-66.
          45.  Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination
             with pioglitazone improves glycaemic control in patients with type 2 diabetes failing
             thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes,
             obesity & metabolism 2007;9(2):166-74.
          46.  Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjornsdottir S, Camisasca RP, et al.
             Effects of vildagliptin on glucose control in patients with type 2 diabetes inade-
             quately controlled with a sulphonylurea. Diabetes, obesity & metabolism 2008;
             10(11):1047-56.
          47.  Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin
             monotherapy in treatment-naive patients with type 2 diabetes. Current medical
             research and opinion 2009;25(10):2401-11.
          48.  Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in
             combination with metformin as initial therapy improves glycaemic control in
             patients with type 2 diabetes compared with either monotherapy: a randomized
             controlled trial. Diabetes, obesity & metabolism 2009;11(6):611-22.
          49.  DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al.
             The efficacy and safety of saxagliptin when added to metformin therapy in
             patients with inadequately controlled type 2 diabetes with metformin alone.
             Diabetes care 2009;32(9):1649-55.
          50.  DeFronzo RA, et al. Once-Daily Saxagliptin Added to Metformin Provides Sustained
             Glycemic Control and Is Well Tolerated Over 102 Weeks in Patients With Type 2
             Diabetes. Diabetes care 2009;58 (Suppl 1):A147, Abstract 547.
          51.  Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior
             to glipizide in patients with type 2 diabetes mellitus inadequately controlled on
             metformin alone: a 52-week randomised controlled trial. International journal of
             clinical practice 2010;64(12):1619-31.
          52.  Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and
             safety of saxagliptin in combination with metformin compared with sitagliptin in
             combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/
             metabolism research and reviews 2010;26(7):540-9.
          53.  Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R, Investigators CV. Initial
             combination therapy with saxagliptin and metformin provides sustained glycaemic
             control and is well tolerated for up to 76 weeks. Diabetes, obesity & metabolism
             2011;13(6):567-76.
          54.  Chacra AR, et al. Saxagliptin added to a submaximal dose of sulphonylurea
             improves glycaemic control compared with uptitration of sulphonylurea in patients
             with type 2 diabetes: a randomised controlled trial. The International Journal of
             Clinical Practice 2009;Published online - doi: 10.1111/j.1742-1241.2009.02143.x.
          55.  Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves
             glycemic control in patients with type 2 diabetes and inadequate control on
             thiazolidinedione alone. The Journal of clinical endocrinology and metabolism
             2009;94(12):4810-9.
          56.  DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl
             peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate
             glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes
             care 2008;31(12):2315-7.
          57.  Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study G. Efficacy and
             safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy
             in patients with type 2 diabetes inadequately controlled with metformin mono
             therapy: a multicentre, randomised, double-blind, placebo-controlled study. Inter-
             national journal of clinical practice 2009;63(1):46-55.
          58.  Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study G. Efficacy and
             safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes
             inadequately controlled by glyburide monotherapy. Diabetes, obesity & metabolism
             2009;11(2):167-76.


                                          76
   71   72   73   74   75   76   77   78   79   80   81